ADAM17 mediates OSCC development in an orthotopic murine modelReport as inadecuate

ADAM17 mediates OSCC development in an orthotopic murine model - Download this document for free, or read online. Document in PDF available to download.

Molecular Cancer

, 13:24

First Online: 05 February 2014Received: 11 September 2013Accepted: 03 February 2014DOI: 10.1186-1476-4598-13-24

Cite this article as: Simabuco, F.M., Kawahara, R., Yokoo, S. et al. Mol Cancer 2014 13: 24. doi:10.1186-1476-4598-13-24


BackgroundADAM17 is one of the main sheddases of the cells and it is responsible for the cleavage and the release of ectodomains of important signaling molecules, such as EGFR ligands. Despite the known crosstalk between ADAM17 and EGFR, which has been considered a promising targeted therapy in oral squamous cell carcinoma OSCC, the role of ADAM17 in OSCC development is not clear.

MethodIn this study the effect of overexpressing ADAM17 in cell migration, viability, adhesion and proliferation was comprehensively appraised in vitro. In addition, the tumor size, tumor proliferative activity, tumor collagenase activity and MS-based proteomics of tumor tissues have been evaluated by injecting tumorigenic squamous carcinoma cells SCC-9 overexpressing ADAM17 in immunodeficient mice.

ResultsThe proteomic analysis has effectively identified a total of 2,194 proteins in control and tumor tissues. Among these, 110 proteins have been down-regulated and 90 have been up-regulated in tumor tissues. Biological network analysis has uncovered that overexpression of ADAM17 regulates Erk pathway in OSCC and further indicates proteins regulated by the overexpression of ADAM17 in the respective pathway. These results are also supported by the evidences of higher viability, migration, adhesion and proliferation in SCC-9 or A431 cells in vitro along with the increase of tumor size and proliferative activity and higher tissue collagenase activity as an outcome of ADAM17 overexpression.

ConclusionThese findings contribute to understand the role of ADAM17 in oral cancer development and as a potential therapeutic target in oral cancer. In addition, our study also provides the basis for the development of novel and refined OSCC-targeting approaches.

Electronic supplementary materialThe online version of this article doi:10.1186-1476-4598-13-24 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Fernando Moreira Simabuco - Rebeca Kawahara - Sami Yokoo - Daniela C Granato - Lucas Miguel - Michelle Agostini - Annelize


Related documents